Myriad Genetics (MYGN) Tops Q2 EPS by 7c, Beats on Revenues; 'Raises Financial Guidance for Fiscal Year 2018'

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.31, $0.07 better than the analyst estimate of $0.24. Revenue for the quarter came in at $194 million versus the consensus estimate of $188.8 million.

• Total Revenues of $194.0 Million
• GAAP Diluted EPS of $0.45
• Adjusted EPS of $0.31 Up 19 Percent
• Company Raises Financial Guidance for Fiscal Year 2018

GUIDANCE:

Myriad Genetics sees FY2018 EPS of $1.11-$1.16, versus the consensus of $1.05. Myriad Genetics sees FY2018 revenue of $760-770 million, versus the consensus of $770.24 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• C.H. Robinson acquires DeSpir Logistics for $75 million
• Sun Communities names Ileana McAlary as general counsel and EVP